WHAT WE DO

Pharmaceuticals Division

We manufacture APIs and intermediates, with strengths in chiral chemistry, custom synthesis, and contract research. We support global partners from gram- to kilogram- to tonne-scale production, backed by advanced facilities, regulatory compliance, and long-standing relationships with major pharma companies.

Manufactured Capital

1,600 m^3
Capacity

Human Capital

2,061
Employees

218
Personnel in R&T and technical services

Financial Capital

INR 11,681 Million
Revenue

INR 1,374 Million
EBIT

47% YoY growth

327 bps
YoY increase in EBIT margin, driven by operating leverage

Serving
Pharmaceutical companies from early-stage development till commercial launch of chemical entities

Offerings
- Contract development and manufacturing
- APIs and intermediates
- Food ingredients and additives

Partnerships
Global pharmaceutical companies looking for commercial supply, contract research, custom synthesis and custom manufacturing of intermediates and APIs

Key Performance Indicators

Parameters	Overall Asset Base	Pharmaceutical Asset Base
Production Sites	5	3
Production Blocks	24	14
Integrated R&T Centre	1	1
No. of Active DMFs	-	69
Key Commercialised APIs	56	31
Total Employees	2,960	1,950
Capacity	4,100 m^3	1,600 m^3
Active Ingredients Sold in 2024-25	7,200 MT	2,850 MT
Advanced Intermediates Sold in 2024-25	1,200 MT	440 MT

The Hikal Advantage

Proven Expertise

Extensive experience in custom synthesis, contract research, and product development for global innovator companies.

Strong R&D and Scale-up Capabilities

End-to-end development across the life sciences value chain, with lab-to-commercial scale-up and a high-potency lab at Pune R&T centre.

Globally Compliant Operations

Regulatory approvals from ANVISA GMP, US FDA (cGMP), TGA-GMP, KFDA (Korea), PMDA (Japan), AFMPS (Belgium), EDQM, EPA, and COFEPRIS (Mexico), and GMP-compliant Pharmaceuticals facility.

Our Capabilities



Our Products

Anti-convulsant	Anti-inflammatory	Analgesic	Anti-parasitic
Anti-lipemic	Anti-histaminic	Anti-depressant	Anti-psychotic
Anti-emetic	Anti-diabetic	Anti-thrombotic	Anti-viral
Haemorheologic			

Business Highlights for 2024-25

- Operational excellence and improved capacity utilisation continued to drive cost efficiency, innovation, and regulatory alignment across the business
- The CDMO segment maintains a robust pipeline from global innovators, with 12-15 new early-stage opportunities under discussion
- Late-stage CDMO programmes are progressed well, with two NCE starting material projects in Phase III trials targeting commercialisation by 2026-27, with the food ingredient project is on track to reach peak revenue in the next 2–3 years
- The API business delivered consistent growth, backed by a strong pipeline of 8–9 differentiated products, with plans to commercialise 2-3 products annually and a strategic focus on complex, high-growth therapeutic areas
- We continue to expand our market presence across Japan, Latin America, Korea, the Middle East, and the Southeast Asia